Cargando…

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties

BACKGROUND: There is a need for improved antibiotic formulations for the treatment of acute bacterial skin and soft structure infection (ABSSSI), especially with the rise of antimicrobial resistance among Gram-positive bacteria. A new formulation of oritavancin was developed to reduce intravenous in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoover, Randall K, Krsak, Martin, Molina, Kyle C, Shah, Kairav, Redell, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982769/ https://www.ncbi.nlm.nih.gov/pubmed/35392455 http://dx.doi.org/10.1093/ofid/ofac090

Ejemplares similares

A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program
por: Redell, Mark, et al.
Publicado: (2018)

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Kimyrsa and Orbactiv – A Tale of Two Formulations
por: Jackson, Brittany T, et al.
Publicado: (2023)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
por: Redell, Mark
Publicado: (2020)

Pharmacokinetic Evaluation of Cefazolin in the Cerebrospinal Fluid of Critically Ill Patients
por: Novak, Alison R, et al.
Publicado: (2021)

Comparison of Sequential Dalbavancin With Standard-of-Care Treatment for Staphylococcus aureus Bloodstream Infections
por: Molina, Kyle C, et al.
Publicado: (2022)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums
por: Goldstein, Ellie J C, et al.
Publicado: (2020)

443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

Long-Acting Lipoglycopeptides: “Lineless Antibiotics” for Serious Infections in Persons Who Use Drugs
por: Morrisette, Taylor, et al.
Publicado: (2019)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
por: Stewart, Cassie L., et al.
Publicado: (2017)

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
por: Rose, Warren E., et al.
Publicado: (2020)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

1606. Distinct Effectiveness of Oritavancin Against Tolerance-Induced Staphylococcus aureus
por: Harven, Lauren, et al.
Publicado: (2020)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
por: Mitra, Subhashis, et al.
Publicado: (2015)

Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis
por: Johnson, Jennifer A., et al.
Publicado: (2015)

Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs
por: Ahiskali, Aileen, et al.
Publicado: (2020)

Clinical Impact of Ceftriaxone Resistance in Escherichia coli Bloodstream Infections: A Multicenter Prospective Cohort Study
por: Tamma, Pranita D, et al.
Publicado: (2022)

In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium
por: Lagatolla, Cristina, et al.
Publicado: (2022)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

Response to Mahatanan and Kang: It's Complicated
por: Molina, Kyle C, et al.
Publicado: (2023)

Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents
por: Miller, Matthew A, et al.
Publicado: (2020)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study
por: Van Hise, Nicholas W., et al.
Publicado: (2020)

Activity of Oritavancin and Its Synergy with Other Antibiotics against Mycobacterium abscessus Infection In Vitro and In Vivo
por: Wang, Gaoyan, et al.
Publicado: (2021)

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin
por: Aerts, Roy, et al.
Publicado: (2022)

Key challenges for implementing a Canadian-based objective structured clinical examination (OSCE) in a Middle Eastern context
por: Wilby, Kyle John, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vj3uf7rpvrbvmg0vug7l7nihi1